News & Updates

Patients with potentially resectable hepatocellular carcinoma (HCC) may receive neoadjuvant nivolumab plus ipilimumab therapy, followed by surgery, to improve their survival, suggests a study.

The combination of adjuvant abemaciclib and endocrine therapy (ET) significantly improves overall survival in patients with HR-positive, HER2-negative, node-positive, high-risk early breast cancer compared with ET alone, the phase III monarchE trial has shown.

A study presented at ASCO GI 2026 shows that colorectal cancer (CRC) survivors who remain physically active, particularly through walking, are less likely to experience severe fatigue and more likely to report better quality of life (QoL).

In the phase III COMMIT* trial, a combination of mFOLFOX6 (FFX), atezolizumab, and bevacizumab significantly improves progression-free survival (PFS) in patients with deficient mismatch repair or microsatellite instability-high metastatic colorectal cancer (dMMR/MSI-H mCRC).